Posted by Michael Wonder on 06 Jul 2023
FDA converts novel Alzheimer’s disease treatment to traditional approval
6 July 2023 - Action follows confirmatory trial to verify clinical benefit.
Today, the US FDA converted Leqembi (lecanemab-irmb), indicated to treat adult patients with Alzheimer’s Disease, to traditional approval following a determination that a confirmatory trial verified clinical benefit.
